Loading...
•
Jun 30, 2020
Cabaletta Bio Q2 2020 Earnings Report
Cabaletta Bio announced financial results for the second quarter ended June 30, 2020 and provided a business update.
Key Takeaways
Cabaletta Bio reported R&D expenses of $5.3 million and G&A expenses of $2.9 million for the three months ended June 30, 2020. As of June 30, 2020, cash, cash equivalents and investments totaled $123.2 million.
Patient recruitment initiated in DesCAARTesTM Phase 1 trial for mucosal pemphigus vulgaris.
IND-enabling studies ongoing for MuSK-CAART program targeting myasthenia gravis, with IND submission anticipated in the second half of 2021.
Three new undisclosed disease targets added to pipeline through expansion of Sponsored Research Agreement with the University of Pennsylvania.
Gene editing research and collaboration agreement signed with Artisan Bio to develop next-generation CAAR T cell therapies.
Forward Guidance
Cabaletta Bio expects that its cash and cash equivalents and investments as of June 30, 2020 will enable it to fund its operating plan through at least the third quarter of 2022.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...